Skip to main content

Baker Julian's Form 4 filing

Neurogene Inc.NGNE ยท filed Aug 17, 2023

Accession no.
0001209191-23-046351
Filed
Aug 17, 2023, 5:08 PM ET
Trade date
Aug 15-17, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 12 non-derivative transactions. Open-market purchases total $1.46M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Baker JulianCIK 0001087939Director, 10% Owner
Baker FelixCIK 0001087940Director, 10% Owner
Baker Bros. Advisors LPCIK 0001263508Director, 10% Owner
Baker Brothers Life Sciences LPCIK 0001363364Director, 10% Owner
667, L.P.CIK 0001551139Director, 10% Owner
Baker Bros. Advisors (GP) LLCCIK 0001580575Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2023Common StockPPurchaseAcquired+143,519$0.6308F3+$90,531.79463,568Indirect
Aug 15, 2023Common StockPPurchaseAcquired+1,740,581$0.6308F3+$1,097,958.495,242,272Indirect
Aug 15, 2023Common StockPPurchaseAcquired+358$0.665+$238.07463,926Indirect
Aug 15, 2023Common StockPPurchaseAcquired+4,342$0.665+$2,887.435,246,614Indirect
Aug 16, 2023Common StockPPurchaseAcquired+17,124$0.6805F8+$11,652.88481,050Indirect
Aug 16, 2023Common StockPPurchaseAcquired+207,676$0.6805F8+$141,323.525,454,290Indirect
Aug 16, 2023Common StockPPurchaseAcquired+366$0.6828+$249.9481,416Indirect
Aug 16, 2023Common StockPPurchaseAcquired+4,434$0.6828+$3,027.545,458,724Indirect
Aug 17, 2023Common StockPPurchaseAcquired+7,676$0.6924F9+$5,314.86489,092Indirect
Aug 17, 2023Common StockPPurchaseAcquired+93,091$0.6924F9+$64,456.215,551,815Indirect
Aug 17, 2023Common StockPPurchaseAcquired+5,041$0.6928F10+$3,492.4494,133Indirect
Aug 17, 2023Common StockPPurchaseAcquired+61,134$0.6928F10+$42,353.645,612,949Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $0.615 to $0.68, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $0.6701 to $0.6991, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $0.6899 to $0.7100, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $0.6800 to $0.7065, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

Remarks

M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP, is a director of Neoleukin Therapeutics, Inc. (the "Issuer"). For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization by virtue of their representation on the board of directors of the Issuer.

Read the full filing on SEC EDGAR (opens in a new tab)